55 related articles for article (PubMed ID: 38434525)
1. [Elucidation of the pathogenesis and treatment of acute myeloid leukemia in animal models].
Itoh-Nakadai A
Rinsho Ketsueki; 2022; 63(9):1078-1082. PubMed ID: 36198532
[TBL] [Abstract][Full Text] [Related]
2. Immunodeficient mouse models of lymphoid tumors.
Imada K
Int J Hematol; 2003 May; 77(4):336-41. PubMed ID: 12774920
[TBL] [Abstract][Full Text] [Related]
3. Immunodeficient NBSGW mouse strain allows chemotherapy modeling in AML patient-derived xenografts.
Dembitz V; Durko J; Campos J; James SC; Lawson H; Kranc KR; Gallipoli P
Hemasphere; 2024 Jan; 8(1):e28. PubMed ID: 38434525
[No Abstract] [Full Text] [Related]
4. Nonirradiated NOD,B6.SCID Il2rγ-/- Kit(W41/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells.
McIntosh BE; Brown ME; Duffin BM; Maufort JP; Vereide DT; Slukvin II; Thomson JA
Stem Cell Reports; 2015 Feb; 4(2):171-80. PubMed ID: 25601207
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells.
Kawashima N; Ishikawa Y; Kim JH; Ushijima Y; Akashi A; Yamaguchi Y; Hattori H; Nakashima M; Ikeno S; Kihara R; Nishiyama T; Morishita T; Watamoto K; Ozawa Y; Kitamura K; Kiyoi H
Nat Commun; 2022 Mar; 13(1):1624. PubMed ID: 35338146
[TBL] [Abstract][Full Text] [Related]
6. Modeling Tumor Immunology and Immunotherapy in Mice.
Buqué A; Galluzzi L
Trends Cancer; 2018 Sep; 4(9):599-601. PubMed ID: 30149876
[TBL] [Abstract][Full Text] [Related]
7. Development of LT-HSC-Reconstituted Non-Irradiated NBSGW Mice for the Study of Human Hematopoiesis
Adigbli G; Hua P; Uchiyama M; Roberts I; Hester J; Watt SM; Issa F
Front Immunol; 2021; 12():642198. PubMed ID: 33868276
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Busulfan Reduces Human CD34
Leonard A; Yapundich M; Nassehi T; Gamer J; Drysdale CM; Haro-Mora JJ; Demirci S; Hsieh MM; Uchida N; Tisdale JF
Mol Ther Methods Clin Dev; 2019 Dec; 15():430-437. PubMed ID: 31890735
[TBL] [Abstract][Full Text] [Related]
9. Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death.
Woodley K; Dillingh LS; Giotopoulos G; Madrigal P; Rattigan KM; Philippe C; Dembitz V; Magee AMS; Asby R; van de Lagemaat LN; Mapperley C; James SC; Prehn JHM; Tzelepis K; Rouault-Pierre K; Vassiliou GS; Kranc KR; Helgason GV; Huntly BJP; Gallipoli P
Nat Commun; 2023 Apr; 14(1):2132. PubMed ID: 37059720
[TBL] [Abstract][Full Text] [Related]
10. CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia.
Grey W; Rio-Machin A; Casado P; Grönroos E; Ali S; Miettinen JJ; Bewicke-Copley F; Parsons A; Heckman CA; Swanton C; Cutillas PR; Gribben J; Fitzgibbon J; Bonnet D
Sci Transl Med; 2022 Jun; 14(650):eabn3248. PubMed ID: 35731890
[TBL] [Abstract][Full Text] [Related]
11. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia.
Zeng AGX; Bansal S; Jin L; Mitchell A; Chen WC; Abbas HA; Chan-Seng-Yue M; Voisin V; van Galen P; Tierens A; Cheok M; Preudhomme C; Dombret H; Daver N; Futreal PA; Minden MD; Kennedy JA; Wang JCY; Dick JE
Nat Med; 2022 Jun; 28(6):1212-1223. PubMed ID: 35618837
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress.
Bonagas N; Gustafsson NMS; Henriksson M; Marttila P; Gustafsson R; Wiita E; Borhade S; Green AC; Vallin KSA; Sarno A; Svensson R; Göktürk C; Pham T; Jemth AS; Loseva O; Cookson V; Kiweler N; Sandberg L; Rasti A; Unterlass JE; Haraldsson M; Andersson Y; Scaletti ER; Bengtsson C; Paulin CBJ; Sanjiv K; Abdurakhmanov E; Pudelko L; Kunz B; Desroses M; Iliev P; Färnegårdh K; Krämer A; Garg N; Michel M; Häggblad S; Jarvius M; Kalderén C; Jensen AB; Almlöf I; Karsten S; Zhang SM; Häggblad M; Eriksson A; Liu J; Glinghammar B; Nekhotiaeva N; Klingegård F; Koolmeister T; Martens U; Llona-Minguez S; Moulson R; Nordström H; Parrow V; Dahllund L; Sjöberg B; Vargas IL; Vo DD; Wannberg J; Knapp S; Krokan HE; Arvidsson PI; Scobie M; Meiser J; Stenmark P; Berglund UW; Homan EJ; Helleday T
Nat Cancer; 2022 Feb; 3(2):156-172. PubMed ID: 35228749
[TBL] [Abstract][Full Text] [Related]
13. An
Lin S; Larrue C; Scheidegger NK; Seong BKA; Dharia NV; Kuljanin M; Wechsler CS; Kugener G; Robichaud AL; Conway AS; Mashaka T; Mouche S; Adane B; Ryan JA; Mancias JD; Younger ST; Piccioni F; Lee LH; Wunderlich M; Letai A; Tamburini J; Stegmaier K
Cancer Discov; 2022 Feb; 12(2):432-449. PubMed ID: 34531254
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia: 2021 update on risk-stratification and management.
Estey EH
Am J Hematol; 2020 Nov; 95(11):1368-1398. PubMed ID: 32833263
[TBL] [Abstract][Full Text] [Related]
15. Induction of a Timed Metabolic Collapse to Overcome Cancer Chemoresistance.
van Gastel N; Spinelli JB; Sharda A; Schajnovitz A; Baryawno N; Rhee C; Oki T; Grace E; Soled HJ; Milosevic J; Sykes DB; Hsu PP; Vander Heiden MG; Vidoudez C; Trauger SA; Haigis MC; Scadden DT
Cell Metab; 2020 Sep; 32(3):391-403.e6. PubMed ID: 32763164
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
